Duplication of the methyl-CpG-binding protein 2 gene (MECP2) is a rare condition that can result in epilepsy in half of the cases. Although this condition has been well characterized in the literature, there is a lack of research on MECP2 duplication related epilepsy and its management.
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INTRODUCTION

Duplications of Xq28 involving the methyl CpG binding protein 2 gene (MECP2)
causes 0.5 to 2 percent of X-linked developmental disabilities and are predominantly inherited with full penetrance in males [1] . More severe mutations in MECP2 are lethal in males. Females with point mutations in MECP2 present with Rett syndrome. MECP2 duplication syndrome has been well-described in patients with mental retardation, absent to minimal speech, hypotonia replaced by progressive spasticity and/or ataxia, mild facial dysmorphisms (brachycephaly, large face, midface hypoplasia, depressed nasal bridge, upturned nares), and severe recurrent respiratory infections, and death before 25 years of age [2] .
Approximately half of patients with MECP2 duplication also present with epilepsy, although this varies with age. Seizures generally develop in late childhood and early adolescence. Seizures present as polymorphic crises (absences, focal seizures, generalized tonic-clonic) or myoclonic or myoclonic-astatic forms with drop attacks [3] .
The onset of seizures is thought to correlate with neurological deterioration including loss of speech and motor skills.
To date, there are 151 reported patients with MECP2 duplication syndrome, 87 of whom also have epilepsy. For a full summary of the case studies and outcomes, see Table   1 . Most of cases described demonstrate that MECP2-related epilepsy is refractory to pharmacotherapy [4] or there was no reported response. In one case report [5] , the patient responded to valproic acid initially, but seizures recurred after two years. Caumes et al. [4] reported seven patients on VPA, only one of which responded with complete control of atypical absence seizures at the 3-year follow-up. Another more recent study
, two patients showed response with complete resolution of seizures with VPA in one case and a combination of VPA, clobazam, and lamotrigine in the other case. Limited research exists on patient attributes and epilepsy characteristics that make these patients responsive to therapy.
We describe an eleven-year old boy with MECP2-related epilepsy, who responded to VPA initially and upon re-challenge. This case provides evidence of the efficacy of VPA as a first-line monotherapy for treatment of MECP2 related epilepsy.
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CASE REPORT
An eleven-year old boy was evaluated in the Neurology clinic. He was born at 39
weeks via emergency C-section in a pregnancy complicated by preeclampsia. Maternal history was significant for three prior miscarriages. There were no teratogen exposures during pregnancy. He was healthy with the exception of severe constipation as an infant.
He had global developmental delays. He sat at 6 months, walked independently at 24 months, and was unable to ride a bike. He also had fine motor difficulties, particularly with writing letters and using utensils. The patient was started on Valproic Acid (VPA) at 10mL BID to be continued for two years. Since starting VPA, he was seizure-free. His brother, who was found to have the same MeCP2 duplication, and also remained seizure free on VPA.
However, due to findings of thrombocytopenia and hyperbilirubinemia in the proband, the VPA was stopped. Following the discontinuation of VPA, he had a reemergence of his epilepsy with an increase in his drop seizures. He was trialed on a multitude of other anticonvulsants, including Levetiracetam, Lamotrigine, Oxcarbazepine, Lacosamide, Clobazam, and Topiramate with no success. Given that the patient remained refractory to polytherapy and that the reported hyperbilirubinemia is a very rare occurrence, the VPA was re-started with close monitoring of transaminases and bilirubin levels. Upon re-challenge, all his convulsive seizures were controlled with a significant decrease in frequency of his drop attacks occurring 1-2 times daily.
Laboratory studies showed a normalization of platelets and bilirubin levels.
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DISCUSSION
This case study describes a patient with MECP2-related epilepsy who had an initial favorable response to Valproic acid (VPA), followed by discontinuation of therapy and re-emergence of symptoms, and subsequently a re-challenge of VPA which achieved seizure control. This study provides unique evidence for the efficacy of VPA as an initial monotherapy in MECP2 duplication-related epilepsy.
The majority of previous cases of MECP2 duplication-related epilepsy in the literature have shown poor response to therapy or drug resistance. In one case series [6] , two The current case and the two previously documented reports demonstrate that seizure activity in MECP2 duplication syndrome can be responsive to VPA. The mechanism of action of VPA is not fully understood, but it is thought to act via multiple pathways
including blockage of voltage-gated sodium channels and increased levels of gammaaminobutyric acid (GABA) [7] . This generalized mechanism makes VPA an ideal initial antiepileptic in MECP2-duplication related epilepsy.
It is unknown as to which factors differentiate patients who were refractory to treatment versus those who responded to VPA. The difference may reflect varying genetic modifiers modulating the complex epileptic networks in MECP2 duplication syndrome. The types of seizures in the responsive patients may also be different than the non-responders. In the previous studies, one treatment responder displayed atypical absence seizures exclusively [4] and the other two demonstrated atonic head drops and drop attacks respectively [6] . Our patient also predominantly had drop attacks as compared to other seizure types. This is in contrast to the many of non-responders who had seizures of multiple types resembling Lennox-Gestalt syndrome. This observation, however, requires further study in a larger patient sample.
Nevertheless, the underlying seizure types that occur in MECP2-related epilepsy are well-suited to the generalized effects of VPA. Previous cases of MECP2 duplication syndrome demonstrate that seizures are often polymorphic occurring frequently in the form of generalized tonic-clonic, atypical absence, atonic, and myoclonic seizures [6] . As such, an antiepileptic drug with a broad spectrum of activity is a good initial show abnormal background activity with high voltage spindles [6] . This EEG pattern closely reflects activity present in myoclonic seizures and genetic generalized epilepsy syndromes. Given the widespread nature of cortical activity, VPA is a good choice given its multiple mechanisms of action.
VPA is a also viable option in MECP2 duplication syndrome as a majority of patients are males and do not have the added risk of pregnancy-related complications including teratogenicity. Current evidence states that VPA is the first-choice treatment option in males and post-menopausal women, while it is not recommended for use in women of child-bearing age and patients with obesity [8] . In these contraindicated cases, Lamotrigine can be used as an alternative agent. Lamotrigine is a phenyltriazine derivative that has a similar mechanism of action than VPA in that it inhibits voltageactivated sodium channels. As discussed, in a patient previously reported in the literature who responded to a combination of VPA and lamotrigine, lamotrigine served to augment the efficacy of VPA in controlling generalized seizures. This represents an additional reason for starting on VPA as an initial monotherapy as it can be combined with Lamotrigine in the case of treatment resistance [9] .
Despite the fact that VPA is the most effective monotherapy with lower treatment withdrawal in generalized epilepsy, the adverse event and side effect profile must be taken into consideration. VPA has multiple side effects including weight gain, hair loss, gynecomastia [10] . In the current case, there was the additional issue of thrombocytopenia, which is a well-described hematological side effect of VPA.
However, thrombocytopenia alone is not an indication to discontinue treatment, and
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A C C E P T E D M A N U S C R I P T 12 recent evidence suggests that a reduction in dose with strict laboratory controls can be sufficient to normalize patient values [11] . Furthermore, while hepatotoxicity is common, there are no reported cases of hyperbilirubinemia in VPA, suggesting that this finding in our patient was either incidental or due to an unrelated etiology. As such, the patient was appropriately re-trialled on VPA with reduction of the dosage and close monitoring of platelets and transaminases.
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